COMMUNIQUÉS West-GlobeNewswire

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
27/10/2026
Nes-Ziona, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced receipt of a delisting [...]
Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform
27/10/2026
– Firefly’s AI foundation model, being built on more than 200,000 standardized EEG/ERP brain scans, bolsters its long-term BCI growth opportunity – – With over 3,000 Versus headsets shipped, the platform generates [...]
Meet Patel's Passion Farms Reports 20% Year-Over-Year Growth Across Multi-State Operations
27/10/2026
Houston-based wholesaler reports a 20% revenue increase for the first nine months of 2026, matching the 20% annual growth it recorded in 2024 and 2025 HOUSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Passion Farms , a Houston [...]
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
27/10/2026
Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company [...]
Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET
27/10/2026
HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on November 10, 2026, and [...]
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
27/10/2026
Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers Advancing WVE-007 (INHBE siRNA) across treatment settings [...]
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
27/10/2026
Company to provide latest clinical trial data and highlight evolving approaches to leptomeningeal metastases diagnosis and treatment in a company sponsored symposium 2026 SNO Annual Meeting to be held on November 12-15 [...]
Medicus Pharma to Present at BioFuture and Global Biotechnology Summit
27/10/2026
Company’s Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi PHILADELPHIA, Oct. 27, 2026 (GLOBE [...]
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
27/10/2026
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported findings; however, [...]
InflaRx Announces November Investor Events
27/10/2026
Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar [...]
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
27/10/2026
– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal [...]
Peptide Stacks: Kylo Peptides Brings Wolverine, GLOW and KLOW Into One Research Stack Line
27/10/2026
Sheridan, Wyoming, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ] has combined its Wolverine, GLOW, and KLOW peptide stacks into a single research stack line in its catalog. The company [...]
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
27/10/2026
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a [...]
Mammogen and MammoLink Partner to Advance a New Model for Community-Based Breast Cancer Detection
27/10/2026
MammoLink joins Mammogen’s KATELYN-ERIN trial, expanding community access to a prospective study evaluating blood-based RNA biology for breast cancer detection NEWPORT BEACH, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- [...]
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
27/10/2026
Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA Study expands immunology portfolio into autoimmune cytopenias, evaluating a [...]
Fortrea to Participate in Jefferies Global Healthcare Conference
27/10/2026
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor [...]
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
27/10/2026
SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel [...]
Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
27/10/2026
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for [...]
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
27/10/2026
PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]

Pages